Company intelligence / Profile preview

IRIS Research and Development

Plantation, Florida, USAdnb.com ↗

Ownership: Private
Development stage: Other

Overview

No proprietary results; participates as an investigational site in sponsor-led trials. Trials listed include those for HZN-1116, cenerimod, risankizumab, afimetoran, baricitinib, upadacitinib, PF‑06823859, HZN‑825 among others. These are sponsor drugs; the company does not own or develop these assets.

Therapeutic areas: ImmunologyRheumatology
Industry: Contract Research Organization

Partnerships

Pharmaceutical sponsors by serving as an investigational trial site.

Beyond the preview

Go deeper on IRIS Research and Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IRIS Research and Development.

Explore the full profile